Targeted treatment for osteoarthritis: drugs and delivery system

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Osteoarthritis (OA) management is complex due to the avascular, dense, and occluded joint tissue structure.
• Despite extensive research, the pathogenesis and progression of OA remain incompletely understood.
• Traditional OA treatments are being augmented by novel drug development and advanced delivery strategies.

Purpose of the Study:

• To review current nanoparticle (NP)-based drug delivery systems (DDS) for intra-articular (IA) administration in OA treatment.
• To explore the potential of modified OA drugs and bioadaptive carriers to enhance IA treatment efficacy.
• To address discrepancies between in vitro and in vivo drug release and investigate drug-nanocarrier interactions for novel OA therapeutic approaches.

Main Methods:

• Review of scientific literature on nanoparticle drug delivery systems for intra-articular administration in osteoarthritis.
• Analysis of drug modification and bioadaptive carrier synthesis for enhanced efficacy.
• Exploration of nanomaterial properties, including biocompatibility and drug loading-release capabilities.

Main Results:

• Nanoparticles (NPs) demonstrate significant improvements in drug penetration and retention within the OA joint.
• Targeted nanomaterial delivery systems exhibit excellent biocompatibility and controlled drug loading and release.
• Advances in drug modification and carrier synthesis are leading to improved intra-articular treatment outcomes.

Conclusions:

• Nanomaterial-based drug delivery systems offer a promising avenue for enhancing intra-articular treatments for osteoarthritis.
• Further research into drug-nanocarrier interactions and in vitro-in vivo release profiles is crucial for optimizing OA therapy.
• Targeted nanoparticle delivery systems represent a significant advancement in addressing the challenges of OA management.